anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a compound traditional Chinese medicine oral pill, in particular to a traditional Chinese medicine preparation for treating sudden deafness, tinnitus and the like. The sudden deafness is also known as idiopathic sudden deafness, which is idiopathic and cryptogenic sensorineural deafness. The pill adopts a theory of assistant and guide, and yin-yang supplement in the traditional Chinese medicine theory to treat the sudden deafness. The compound traditional Chinese medicine pill accords with the traditional Chinese medicine theory, has an all-natural formula, has obvious effects on treating the tinnitus and the deafness, and is small in side effect. In addition, a medicinal material source is wide; a technology is simple; and the pill can be produced on a large scale to meet requirements of patients. The pill adopts the technical scheme that the pill comprises the following medicinal materials by percentage: 15% of fructus forsythia, 15% of rhizoma acori graminei, 10% of burdock, 10% of radix bupleuri, 10% of scutellaria baicalensis georgi, 10% of platycodon grandiflorum, 6% of liquorice, 6% of radix angelicae, 6% of wild chrysanthemum, 6% of radix paeoniae rubra, 3% of cordycepic acid, and 3% of astragaloside; the 12 drugs are porphyrized according to the proportion, and uniformly stirred to form the pill or a tablet. A patient takes 1.5-2g pill every time for three times per day, swallows the pill with warm boiled water after a meal, and takes the pill for 7-10 days continuously.
Tizanidine is an α2-adrenergic agonist that can produce hypotension [see Adverse Reactions (6.1) and Drug Interactions (7.5)]. Syncope has been reported in patients treated with tizanidine in the postmarketing setting. The risk of hypotension may be minimized by dose titration; monitoring for signs and symptoms of hypotension prior to dosage increase may minimize the risks associated with hypotension. In addition, patients moving from a supine to fixed upright position may be at increased risk for hypotension and orthostatic effects.

Monitor for hypotension when tizanidine is used in patients receiving concurrent antihypertensive therapy. It is not recommended that tizanidine be used with other α2-adrenergic agonists. Clinically significant hypotension (decreases in both systolic and diastolic pressure) has been reported with concomitant administration of tizanidine and strong CYP1A2 inhibitors [see Clinical Pharmacology (12.3)]. Therefore, concomitant use of tizanidine with strong CYP1A2 inhibitors is contraindicated [see Contraindications (4) and Drug Interactions (7.1)].
About 57.000 people are diagnosed with brain tumors or other central nervous system tumors in Europe every year. Radiotherapy is currently the most common tool in the treatment of this disease. Unfortunately, radiation treatment is associated with neurocognitive sequelae that make brain cancer survivors to undergo an accelerating aging. These side effects have been related to the radiation impact on the neurogenic niches and to the inflammatory processes caused by radiation. In this context, mesenchymal stem cell (MSCs) therapy has emerged as a promising tool for the prevention of radiation damages and improvement of the neurological functions. Our preliminary study indicates that MSCs protect neurogenesis in the irradiated mouse brain, as well as reduces neuroinflammation. These observations lead to suggest that MSCs therapy will prevent neurocognitive sequelae in mice receiving radiation. Results derived from this study will provide a new approach to minimize radiation damage during brain tumor treatment, improving life and healthspan of millions of patients.
The present study aims to address disparities in cannabis use outcomes among African American/Black (hereby referred to as Black) adults with cannabis use disorder (CUD). African American/Black adults are more likely to endorse cannabis use patterns that are more severe (weekly and blunt use) and meet diagnostic criteria for cannabis use disorder (CUD) than White adults (16.8% vs 10.0%). This finding is alarming as cannabis use disorder is associated with more severe psychosocial risk profiles, including poly-substance use, psychiatric problems, and legal trouble relative to non-CUD use and non-use. Additionally, although Black cannabis users are more likely to report being ready to quit and a recent quit attempt relative to White cannabis users, this population is less likely to seek in-person treatment relative to White cannabis users because of individual (e.g., beliefs about use), community (e.g., neighborhood attitudes about use), and institutional (e.g., healthcare access) factors as well as due to institutionalized racism and discrimination (e.g., more likely to not be listened to by practitioners). Targeted, accessible, and culturally adapted therapeutic programming is needed to reduce risk and improve disparities for poor cannabis-related outcomes among Black adults with cannabis use disorder. These findings are significant because they contribute to heath, social, and psychological health disparities within the Black community. Psycho-sociocultural models of substance use posit that Black individuals may use cannabis and continue using despite cannabis-related problems including cannabis use disorder, to manage psychological distress associated with stressors associated with minority status, such as racial discrimination. Therefore, the present study seeks to develop a culturally adapted, mobile app tailored specifically for Black cannabis users (CT-MICART). Using the expert opinion and feedback from the community Research Advisory Board (CRAB), the investigative team will pilot test CT-MICART and focus on analysis of data collected to help achieve a better culturally tailored app.
A pharmaceutical composition can be formed by preparing core particles comprising the active agent topiramate, drying the particles to form dried core particles and then coating the dried particles with a taste masking mixture to form coated particles.  The coated particles are then dried to form the composition.  The amount of the taste masking agent ranges from about 7% to about 15% by weight of the pharmaceutical composition.  Also described is a pharmaceutical composition comprising core particles having an initial particle size of between 0.1 mm and 2.5 mm and a taste masking coating that comprises about 7% to about 15% by weight of the composition. The composition can comprise 85 to 93% by weight core beads and 7 to 15% by weight of coating. The core beads comprise 18 to 21% by weight of topiramate and 8-11% by weight of povidone and 58 to 61% by weight of sugar. The coating comprises 6-9% by weight of cellulose acetate and 2 to 5% by weight of povidone.  The compositions can be used for treating convulsion or epilepsy.
Participants received standard of care (SOC) treatment for the first year of the study (SOC-controlled period). At week 52 participants began treatment with evolocumab 420 mg once a month (QM) for 4 years during the all-investigational product \[all-IP\] period.
The participants will receive the same intervention procedures, but the intervention will have no therapeutic effect. Specifically, for the sham stimulation, participants will only experience 30-s ramp-up and 30-s ramp-down periods at both the commencement and end of the stimulation.
BACKGROUND: Stromal fibrosis is highly associated with therapeutic resistance and poor survival in esophageal squamous cell carcinoma (ESCC) patients. Low expression of plasma gelsolin (pGSN), a serum abundant protein, has been found to correlate with inflammation and fibrosis. Here, we evaluated pGSN expression in patients with different stages of cancer and therapeutic responses, and delineated the molecular mechanisms involved to gain insight into therapeutic strategies for ESCC.
METHODS: Circulating pGSN level in ESCC patients was determined by enzyme-linked immunosorbent assay analysis, and the tissue microarray of tumors was analyzed by immunohistochemistry staining. Cell-based studies were performed to investigate cancer behaviors and molecular mechanisms, and mouse models were used to examine the pGSN-induced tumor suppressive effects in vivo.
RESULTS: Circulating pGSN expression is distinctively decreased during ESCC progression, and low pGSN expression correlates with poor therapeutic responses and poor survival. Methylation-specific PCR analysis confirmed that decreased pGSN expression is partly attributed to the hypermethylation of the GSN promoter, the gene encoding pGSN. Importantly, cell-based immunoprecipitation and protein stability assays demonstrated that pGSN competes with oncogenic tenascin-C (TNC) for the binding and degradation of integrin αvβ3, revealing that decreased pGSN expression leads to the promotion of oncogenic signaling transduction in cancer cells and fibroblasts. Furthermore, overexpression of pGSN caused the attenuation of TNC expression and inactivation of cancer-associated fibroblast (CAF), thereby leading to tumor growth inhibition in mice.
CONCLUSIONS: Our results demonstrated that GSN methylation causes decreased secretion of pGSN, leading to integrin dysregulation, oncogenic TNC activation, and CAF formation. These findings highlight the role of pGSN in therapeutic resistance and the fibrotic tumor microenvironment of ESCC.
PURPOSE:An adhesive plaster, containing Zizyphus jujuba or/and SORISHI (a fruit of Rhamnus japonica Maxim.) in a plaster consisting of an adhesive material and the drug present stable without decomposition. CONSTITUTION:An adhesive plaster obtained by incorporating a plaster consisting of an adhesive material, e.g. acrylic material such as n-butyl (meth) acrylate, or rubber based material such as styrene-isoprene-styrene block copolymer rubber, with Zizyphus jujuba (fruit of Zizyphus vulgaris Lam. var. inermis Bynge of the family Rhamnacea) or/and SORISHI (fruit of Rhmnus japonica Maxim. of the above-mentioned family) in an amount of 0.01-20wt% for dried powder and an amount of about 1/2-1/3 based on the above-mentioned amount for hydrolyzate. A tackifier, e.g. terpenic resin, adhesive force and holding power modifier, e.g. liquid paraffin, water and emulsifying agent, etc., may be incorporated further as the third component. Since a compound containing phenolic hydroxyl group, amine based compound, etc., reduce considerably the content thereof among the drug to be incorporated, this plaster is particularly useful for formulating the above-mentioned drug.
BACKGROUND: Breast cancer-related lymphedema (BCRL) is a potentially disabling and often irreversible consequence of breast cancer treatment, caused by the mechanical incompetence of the lymphatic system, resulting in reduced drainage capacity and functional overload due to an excessive volume of interstitial fluid surpassing the system's transport capacity in the arm. We wanted to determine the impact and explore the differences in independent risk factors for the occurrence of BCRL; incidence of BCRL over a five-year period at the Institute of Oncology Vojvodina in Sremska Kamenica and to answer the research question regarding the influence of the prehabilitation program on the overall incidence of BCRL during the observed five-year period.
METHODS: From 2014 to 2018, a retrospective study was conducted at the Institute of Oncology of Vojvodina in Sremska Kamenica, analyzing female patients who had undergone breast cancer surgery.
RESULTS: The study included 150 breast cancer patients who developed secondary lymphedema following surgery with the mean age of 59.2 ± 11.3 years. Fluctuations in hospitalization rates were observed over the five-year period, with the highest number of admissions in 2014 (24.0%) and a decline in 2018 (14.0%). The most common surgical procedure performed was left quadrantectomy (24.0%), followed by right quadrantectomy (20.0%) and left amputation (15.3%). The mean number of removed lymph nodes was 15.2 ± 6.1, with no statistically significant association between the number of removed lymph nodes and the manifestation of secondary lymphedema. The severity of secondary lymphedema varied based on patient age, with a higher incidence of moderate and severe lymphedema observed in patients aged 61 years and older. Patients who underwent radical surgery were more likely to experience severe lymphedema compared to those who had conservative surgery, although this difference was not statistically significant.
CONCLUSION: In our study, the type of surgery, elapsed time since surgery, and the number of removed lymph nodes were not influencing factors for the occurrence of BCRL. However, concerning its severity, a greater number of systemic therapy modalities combined with radiotherapy were associated with a more frequent occurrence of mild and moderate BCRL. Also, the severity of BCRL varied among different age groups, with a higher incidence of moderate and severe lymphedema observed in patients aged 61 years and older. Ultimately, improving the quality of life for individuals affected by secondary lymphedema remains a crucial goal in the field of oncology.
Anastrozole 1 mg PO daily and Sorafenib starting dose 200 mg PO twice a day for 28 day cycle. Expansion group added when MTD dose of Anastrozole + Sorafenib found.
Participants randomized to receive Peer Support will be engaged by participants' own peer counsellor over weeks -2 to 12. Peer counselling will follow a flexible framework for contact with participants, which will include in-person and phone-based check-ins, depending upon individual participant preference. Peer counsellors will visit the counsellors' assigned participant in-person at participants' home, workplace, or other setting based on participant preference at least during weeks -2, 2, 4, 8 and 12; additional in-person contact will be provided upon participant request.
Tablets with two different components, sepd. by a vertical central plane, are produced in eccentric or turntable presses by using separate filling devices for separate compartments created by split bottom plungers. The bottom plunger is split into two halves which are divided by a tongue. The two different mixes of granules are charged through a filling slipper with a partition. After withdrawal of the slipper the tongue is withdrawn flush to the top of the plunger and the top plunger can compress the tablet. An upward movement of the bottom plunger ejects the tablet from the die. The tablets have smaller contact areas between the different components than tablets with a horizontal subdivision. Both parts are kept clearly separate and there is less intermixing between them.
BACKGROUND: There is an ongoing debate as to whether death with sepsis is primarily caused by sepsis or, more often, by the underlying disease. There are no data on the influence of a researcher's background on such an assessment. Therefore, the aim of this analysis was to assess the cause of death in sepsis and the influence of an investigator's professional background on such an assessment.
MATERIALS AND METHODS: We performed a retrospective observational cohort study of sepsis patients treated in the medical intensive care unit (ICU) of a tertiary care center. For deceased patients, comorbidities and severity of illness were documented. The cause of death (sepsis or comorbidities or both combined) was independently assessed by four assessors with different professional backgrounds (medical student, senior physician in the medical ICU, anesthesiological intensivist, and senior physician specialized in the predominant comorbidity).
RESULTS: In all, 78 of 235 patients died in hospital. Agreement between assessors about cause of death was low (κ 0.37, 95% confidence interval 0.29-0.44). Depending on the assessor, sepsis was the sole cause of death in 6-12% of cases, sepsis and comorbidities in 54-76%, and comorbidities alone in 18-40%.
CONCLUSIONS: In a relevant proportion of patients with sepsis treated in the medical ICU, comorbidities contribute significantly to mortality, and death from sepsis without relevant comorbidities is a rare event. Designation of the cause of death in sepsis patients is highly subjective and may be influenced by the professional background of the assessor.
PURPOSE:To impart emulsifying force and emulsion stability equal to or more than that of gum arabic, by emulsifying lecithin with an aqueous starch hydrolysate solution and dissolving xanthan gum to said solution to prepare an emulsifier. CONSTITUTION:alpha-Amylase or an acid is adapted to starch such as corn starch, tapioca starch, sweetpotato starch, potato starch and waxycorn starch etc. to prepare the aqueous solution of the starch hydrolysate. After lecithin added to said solution, xanthan gum is dissolved therein or lecithin and xanthan gum are simultaneously added to the aqueous solution of the starch hydrolysate to not only emulsify lecithin but also the dissolve the xanthane gum to prepare an emulsifier. The use amount of lecithin is pref. about 0.1-5pts.wt. of 100pts. of the starch hydrolysate.
BACKGROUND: The leucine-rich repeat-containing (LRRC) superfamily members are known for their significant roles in tumorigenesis and cellular proliferation. However, the specific regulatory role of LRRC45 in lung cancer remains unexplored. This study investigated the impact and underlying mechanisms of LRRC45 on the proliferative, migratory, and invasive capacities of lung adenocarcinoma (LUAD) cells, potentially identifying new targets for therapeutic intervention.
MATERIAL AND METHODS: The importance of LRRC45 in lung cancer was analyzed using the online databases of UCSC Xena, TCGA, TISIDB, and UALCAN, whereas to detect target gene expression, we used the qRT-PCR, Western blot, and immunofluorescence confocal. The cell growth was monitored by colony formation assay and migration was examined by cell migration assay. Finally, a xenograft mouse tumor model using A549 ​cells was used to explore the in vivo effect of LRRC45 in lung cancer.
RESULTS: Inhibition of LRRC45 expression led to a notable decrease in proliferation, migration, and invasion of A549 and H1299 ​cells. LRRC45 silencing significantly reduced the tumor volume and improved the mice's survival. Additionally, inhibition of LRRC45 expression dramatically suppressed c-MYC, Slug, MMP2, and MMP9 expression. Overexpression of c-MYC and/or Slug in the LRRC45-deficient cells can partially or totally restore the LRRC45 deficiency-suppressed growth. Moreover, the overexpression of MMP2 and/or MMP9 could partially or totally restore LRRC45 deficiency-reduced cell metastasis.
CONCLUSIONS: LRRC45 could promote the proliferative, migrative, and invasive capacities of lung cancer cells by increasing c-MYC, Slug, MMP2, and MMP9 expression, indicating the therapeutic implications and potential significance of these pathways in lung cancer.
The invention discloses a traditional Chinese medicinal composition for treating exogenous fever. The traditional Chinese medicinal composition consists of the following medicinal raw materials in parts by weight: 3-30 parts of scutellaria baicalensis, 3-9 parts of platycodon grandiflorum, 10-30 parts of reed rhizome, 9-30 parts of lalang grass rhizome, 5-9 parts of tussilago farfara, 6-20 parts of rhizoma atractylodis, 4.5-9 parts of apricot kernel and 9-30 parts of herba scutellariae barbatae. In addition, the invention also discloses application of the traditional Chinese medicinal composition. Clinical experiments prove that the traditional Chinese medicinal composition can be used for effectively enhancing the curative effect of immediately bringing down the fever in patients with the exogenous fever, shortening an initial effect time and a fever-relieving time and improving a clinical cure rate. Basic experiments prove that the traditional Chinese medicinal composition disclosed by the invention has a good inhibitory effect on influenza virus (H1N1 type), respiratory syncytial virus and adenovirus. Therefore, the traditional Chinese medicinal composition disclosed by the invention has important meaning and application value for the treatment of the exogenous fever.
Patients receive tivantinib 360 PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.
The BEACON CRC study demonstrated that encorafenib (Enco)+cetuximab (Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux + chemotherapy in previously treated patients with BRAF-V600E-mutant mCRC, providing the basis for the approval of the Enco+Cetux regimen in the United States and the European Union. A greater understanding of biomarkers predictive of response to Enco+Cetux±Bini treatment is of clinical relevance. In this prespecified, exploratory biomarker analysis of the BEACON CRC study, we characterize genomic and transcriptomic correlates of clinical outcomes and acquired resistance mechanisms through integrated clinical and molecular analysis, including whole-exome and -transcriptome tissue sequencing and circulating tumor DNA genomic profiling. Tumors with higher immune signatures showed a trend towards increased OS benefit with Enco+Bini+Cetux. RAS, MAP2K1 and MET alterations were most commonly acquired with Enco+Cetux±Bini, and more frequent in patients with a high baseline cell-cycle gene signature; baseline TP53 mutation was associated with acquired MET amplification. Acquired mutations were subclonal and polyclonal, with evidence of increased tumor mutation rate with Enco+Cetux±Bini and mutational signatures (SBS17a/b). These findings support treatment with Enco+Cetux±Bini for patients with BRAF-V600E-mutant mCRC and provide insights into the biology of response and resistance to MAPK-pathway-targeted therapy. ClinicalTrials.gov registration: NCT02928224.
BACKGROUND: Gastric aspiration is applied in oral and maxillofacial procedures to reduce postoperative vomiting (POV), yet its clinical benefit remains largely uncertain. Our study aimed to determine the role of gastric aspiration in the amelioration of POV by a meta-analysis.
METHODS: With adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, global recognized databases, including PubMed, Embase, and Cochrane Central, were searched to obtain randomized controlled trials (RCTs) investigating the effects of gastric aspiration in oral and maxillofacial surgery. The incidence and the number of episodes of POV and the frequency of rescue antiemetic use were extracted as parametric data for pooled estimation. Funnel plots and Egger's test were utilized to assess bias. The recommendation of evidence was rated by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.
RESULTS: After detailed evaluation, 5 RCTs containing 274 participants were eventually included. The results of pooled estimation indicated that gastric aspiration could not reduce the incidence of POV (risk ratio [95% CI] = 0.94 [0.73, 1.21], P = .621), the number of episodes of POV (standard mean difference [95% CI] = -0.13 [-0.45, 0.19], P = .431) or the frequency of rescue antiemetic use (RR [95% CI] = 0.86 [0.49, 1.52], P = .609). No publication bias was detected by the funnel plot and Egger test. The overall recommendation of evidence was rated low regarding each outcome.
CONCLUSION: Based on current evidence, gastric aspiration is not recommended for oral and maxillofacial surgery. Meanwhile, more large-scale high-quality RCTs are needed.